NSE filing, NSE: BETA. Summary written from the filing by ALFA Finder's alert engine.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,798.40
- Market cap
- ₹1,994 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 38.4×Sector 45.9×
- Promoter holding
- 58.91%-0.19% QoQ
- FII holding
- 1.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Other Announcement
Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.
Beta Drugs Earnings Call Transcript: Key Takeaways
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
- Call
- Guides 25% growth
Beta Drugs Investor Presentation: Key Takeaways
Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.
Beta Drugs Q2 FY27 Results: Net Profit ₹185,507,075 Cr, Up 51.8% YoY
Beta Drugs Ltd reported revenue from operations of ₹1,374,887,594 Cr (+33.0% YoY) and net profit of ₹185,507,075 Cr (+51.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹185,507,075 Cr · +51.8% YoY
Beta Drugs Board Meeting Date
Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.
Beta Drugs Annual General Meeting
Beta Drugs Limited conducted its 21st Annual General Meeting on September 30, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and auditor ratification.
Other board meeting outcome announcements
All →VCU Data Management Board Meeting Outcome
VCU Data Management appointed M/s. Utkarsh Shah & Co. as Secretarial Auditors for five years from FY 2026-27, subject to AGM approval. No monetary amount is disclosed, so this is an auditor appointment intimation.
- Execution
- FY 2026-27 to 2030-31 (five years)
Hardcastle & Waud Manufacturing Company Board Meeting Outcome
The board revoked its earlier Mumbai office shift and approved moving the registered office to Mira Road, Thane. The change awaits shareholder and regulatory approval.
Greenply Industries Board Meeting Outcome
Greenply appoints MSKA & Associates LLP as statutory auditor for five years from the 2027 AGM, subject to shareholder approval. Incumbent BSR & Co. continues until then.
- Execution
- 5 years, from the conclusion of the 37th AGM (2027) to the conclusion of the 42nd AGM (2032)
Greaves Cotton Board Meeting Outcome
Greaves Cotton confirmed its Board met on October 29, 2026, on unaudited half-year results. No new financial figures are disclosed in this filing.
Popular Vehicles and Services Board Meeting Outcome
Popular Vehicles passed a circular resolution approving a routine AOA amendment on the common seal. A postal ballot notice and scrutinizer were also appointed.
R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.